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Sir,
We have read with great interest the article by Bozec et al (2008).
In their study, they evaluated on an orthotopic xenograft model,
the antitumour efficacy of bevacizumab, erlotinib and irradiation,
alone and in combination, on a vascular endothelial growth factor
(VEGF) -secreting human head and neck tumour cell line (CAL33).
They reported a significant primary tumour mass decrease with
drug association but not with bevacizumab alone. And the authors
concluded that the efficacy of the combination of bevacizumab,
erlotinib and RT might be of clinical importance in the manage-
ment of head and neck cancer patients.
This work prompted us to analyse the murine model pertinence.
We tested human endothelial cell proliferation in the presence of
murine or human VEGF. We noticed a characteristic bell-shaped
dose–response curve for both human and murine VEGF in the
absence of bevacizumab (Figure 1). In the presence of the most
efficient concentration of VEGF (12.5mgml
1), we observed a
difference of bevacizumab inhibition between murine and human
VEGF-induced proliferation (Figure 2). The endothelial cell
proliferation with human VEGF was more inhibited when
compared with murine VEGF (with 35 vs 17% of decrease).
Several reasons can explain the inefficacy of bevacizumab when
tested alone to inhibit human tumour progression in a xenograft
mice model: (i) increasing evidences (Liang et al, 2006; Yu et al,
2008) show that bevacizumab fails to neutralise efficiently murine
VEGF because of a weak interaction; (ii) VEGF in sufficient
amounts to promote tumour angiogenesis originates from various
host cells in the body such as platelets, muscle cells, tumour-
associated stromal cells, and in scar (Kerbel, 2008); (iii) murine
VEGF is efficient enough to promote human cell growth.
In our opinion, animal models should not be used to conclude
on the clinical pertinence of bevacizumab, unless animals express a
humanised form of VEGF (Gerber et al, 2007).
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Figure 1 Endothelial cell proliferation assay: HUVECs (human umbilical
vein endothelial cells) were incubated with increasing concentrations of
h-VEGF (human) or m-VEGF (murine).
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Figure 2 Endothelial cell proliferation assay: HUVECs (human umbilical
veinous endothelial cells) were incubated with h-VEGF or m-VEGF
(12.5mgml
1), without and with Bevacizumab.
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Sir,
We read with great attention the letter by Eveno et al,
concerning our article TH/2008/4030R published in Br J Cancer
99/1 July 2008.
The main point of their letter is that murine models are not
suited as evidence of an effect of bevacizumab on tumour growth,
because bevacizumab fails to efficiently neutralise murine VEGF.
Their experiments have been performed in vitro on isolated
endothelial cells, whereas ours have been performed in xeno-
grafted animals. In our conditions human VEGF, produced in very
high quantities by the CAL33 human cancer cells, certainly
outnumbered the murine VEGF at least inside the tumour and in
its immediate environment. It is not excluded that a greater dose of
bevacizumab could perhaps have been more efficient.
Anyway, the purpose of our experiments was not to test the
effect of bevacizumab alone on CAL33 growth but rather its
interaction with erlotinib and radiation.
Another explanation of the lack of efficiency of bevacizumab given
alone could result from the orthotopic model used with a very short
time given to the drug to exhibit its effects (10 days after tumour
cells injection, 7 days after the beginning of treatment) giving
treatment on small tumours at a moment when tumour-driven
angiogenesis is not particularly determinant. What gives credit to
this explanation are the results of another recent study of our group
(Bozec et al, 2008) in which we tested bevacizumab, AZD2171, a
VEGFR tki, and their combination on CAL33 cells growing as a
classical xenograft in the flank of animals. The treatment this time
started when tumour volume reached 250mm
3,1 2d a y sa f t e rt u m o u r
cell injection (i.e., 2 days after tumour collection in the Br J Cancer
article) and the effect of bevacizumab was clearly evident 4 days after
the beginning of treatment and lasted until the end of the
observation period, 26 days after the beginning of treatment.
Moreover, many earlier preclinical studies performed on
xenografted tumours (for review see Gerber and Ferrara, 2005)
demonstrated an effect of bevacizumab on tumour growth.
We agree with Eveno et al that the present animal models are
far from being a perfect representation of the clinical situation
and that animals genetically modified to secrete human VEGF in
place of murine VEGF model could be an improvement to the
present situation.
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